[
    [
        {
            "time": "",
            "original_text": "国内首个新型冠状病毒治疗抗体临床获批 微生物所合作方智飞生物受益几何？",
            "features": {
                "keywords": [
                    "新型冠状病毒",
                    "治疗抗体",
                    "临床获批",
                    "微生物所",
                    "智飞生物"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "医疗健康"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国内首个新型冠状病毒治疗抗体临床获批 微生物所合作方智飞生物受益几何？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]